Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641237 | 0.78 | BRD4 (0.42) | CYP1A2HIF1ABRD4CYP2C19TSHR | |
| SCHEMBL13033085 | 0.76 | PIK3CD (0.36) | ALDH1A1MAPT | |
| SCHEMBL10586684 | 0.75 | CHRNB2 (0.42) | CYP1A2HIF1ABRD4TSHRALDH1A1 | |
| SCHEMBL10017887 | 0.74 | BRD4 (0.36) | CYP1A2HIF1ABRD4ALDH1A1 | |
| SCHEMBL9963113 | 0.71 | BRD4 (0.44) | BRD4CYP2C19ALDH1A1 | |
| SCHEMBL10587633 | 0.70 | PDE4B (0.44) | BRD4ALDH1A1MAPT | |
| SCHEMBL5346726 | 0.70 | CYP1A2 (0.41) | CYP1A2HIF1ABRD4CYP2C19ALDH1A1 | |
| SCHEMBL10394770 | 0.67 | CHRM2 (0.45) | ALDH1A1 | |
| SCHEMBL3310290 | 0.67 | CYP1A2 (0.39) | CYP1A2HIF1ABRD4ALDH1A1CA1 | |
| SCHEMBL20682325 | 0.66 | CYP2C19 (0.39) | CYP1A2HIF1ACYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | CYP1A2 2883/4885HIF1A 1198/4885BRD4 367/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | CYP1A2 3933/4885HIF1A 2051/4885BRD4 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.